Neurocrine Biosciences Inc.

Address: 6027 Edgewood Bend Court

Sponsor Overview

assignment

Specializations

Depressive Disorders

Research activity in major depressive disorder includes adjunctive treatment strategies aimed at improving depressive symptoms, maintaining response over time, and evaluating longer-term tolerability in adults with persistent mood symptoms.

Major depressive disorder
Adjunctive antidepressant therapy
Relapse prevention

The sponsor’s work in this area centers on treatment-resistant and recurrent depression, with emphasis on symptom control and sustained clinical benefit.

Schizophrenia and Related Psychotic Symptoms

Clinical research in schizophrenia spans both outpatient and inpatient settings, with attention to behavioral and psychological symptoms, inadequate response to antipsychotic treatment, and long-term safety of adjunctive options.

Schizophrenia
Behavioral and psychological symptoms
Adjunctive antipsychotic treatment

Trials also address symptom management in adults requiring hospital-based care, reflecting a focus on complex psychiatric illness.

Congenital Adrenal Hyperplasia

Studies in classic congenital adrenal hyperplasia and broader congenital adrenal hyperplasia evaluate adrenal hormone control, glucocorticoid-sparing approaches, and treatment use in very young pediatric patients.

Classic congenital adrenal hyperplasia
Adrenal steroid regulation
Pediatric endocrine disorders

This area includes interest in adrenal androgen control and early-life management of endocrine disease.

Movement Disorders and Dyskinesia

The sponsor supports research on movement disorders, including dyskinesia due to cerebral palsy and chorea in pediatric and adult populations, with evaluation of symptom reduction and functional impact.

Movement disorders
Dyskinesia due to cerebral palsy
Chorea

These studies reflect a therapeutic interest in abnormal involuntary movement syndromes across age groups.

Neurological and Neuropsychiatric Conditions

Additional research extends across broader neurological and neuropsychiatric conditions, including epilepsy and related central nervous system disorders, with exploratory work in healthy participants supporting neuropharmacology programs.

Epilepsy
Neurological and neuropsychiatric conditions
Neuropharmacology

The portfolio includes interest in central nervous system symptom modulation and treatment development across neurological and psychiatric domains.

Sponsored Trials

Trial Name	Country	Status
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia	Bulgaria Hungary Romania	Recruiting
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NBI-1117570 in Hospitalized Adults with Schizophrenia	Bulgaria Poland Romania	Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy	Belgium Italy Poland Portugal Spain	Not Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia	Czechia Germany Italy Romania Slovakia Spain	Not Recruiting
Effect of NBI-921355 on Corticospinal Excitability in Epilepsy	The Netherlands	Recruiting
Efficacy and Safety Evaluation of 9-(4-Cyclohexyloxyphenyl)-7-Methyl-3,4-Dihydropyrazino[2,1-c][1,2,4]Thiadiazine 2,2-Dioxide as Adjunctive Therapy in Major Depressive Disorder	Croatia Czechia Poland	Recruiting
Efficacy and Safety Evaluation of NBI-1065845 as Adjunctive Therapy in Adults with Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial	Bulgaria Lithuania Romania Slovakia	Recruiting
Efficacy and Safety of Direclidine (NBI-1117568) in Hospitalized Adults with Schizophrenia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study	Bulgaria Hungary Romania	Recruiting
Efficacy and Safety of NBI-1065845 as Adjunctive Therapy in Adults with Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Study	Belgium Finland Hungary Latvia	Recruiting
Evaluation of Crinecerfont (NBI-74788) Efficacy and Safety in Adults with Classic Congenital Adrenal Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial	Austria Belgium Bulgaria Czechia France Germany Greece Italy Poland Portugal Spain Sweden	Not Recruiting